Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.81 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.64 |
| ▸ | IGF2R | P11717 | 4/20 | 0.55 |
| ▸ | UMPS | P11172 | 4/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | ATIC | P31939 | 1/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471819 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL5001024 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL16710620 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL4997000 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL187934 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL24450790 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL4308485 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL14016411 | 0.98 | FBP1 (0.78) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL21926734 | 0.98 | FBP1 (0.78) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL22107998 | 0.98 | FBP1 (0.78) | FBP1AMDHD2IGF2RUMPSP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723934-B2 | Compositions and methods for the induction of CD8+ T-cells | KEIO UNIVERSITY (JP) | 2023-08-15 | — | — | US | claimed |
| US-20220133813-A1 | COMPOSITIONS AND METHODS FOR THE INDUCTION OF CD8+ T-CELLS | KEIO UNIVERSITY (JP) | 2022-05-05 | — | — | US | claimed |
| US-9073961-B2 | Substitution derivatives of N6 -benzyladenosine-5′-monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparations containing these compounds | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2015-07-07 | — | — | US | claimed |
| EP-2563801-B1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5´-MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATION CONTAINING THESE COMPOUNDS | Univerzita Palackého v Olomouci (CZ) | 2014-09-24 | — | — | EP | claimed |
| US-20130040908-A1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS | BIOAPEX, S.R.O. (CZ) | 2013-02-14 | — | — | US | claimed |
| EP-0427799-B1 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE | GENSIA PHARMA (US) | 1994-11-30 | — | — | EP | claimed |
| US-20260125713-A1 | PRODUCTION OF MOLECULES BY PERIPLASMIC ENZYMATIC CATALYSIS | BIOC3 (FR) | 2026-05-07 | — | — | US | disclosed |
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | disclosed |
| CN-113710807-B | Microorganisms and methods for producing oxygenates from hexoses | 布拉斯科公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4519442-A1 | PRODUCTION OF MOLECULES BY PERIPLASMIC ENZYMATIC CATALYSIS | BIOC3 (FR) | 2025-03-12 | — | — | EP | disclosed |
| CN-119546770-A | Catalytic production of molecules by periplasmic enzymes | BIOC3公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240392329-A1 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF OXYGENATED COMPOUNDS FROM HEXOSES | BRASKEM S.A. (BR) | 2024-11-28 | — | — | US | disclosed |
| US-12006526-B2 | Microorganisms and methods for the production of oxygenated compounds from hexoses | BRASKEM S.A. (BR) | 2024-06-11 | — | — | US | disclosed |
| US-6379911-B2 | ANALYZING NUCLEOSIDE HYDROLASES; DETECTING PARASITES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-04-30 | — | — | US | disclosed |
| US-20010019823-A1 | ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-06 | — | — | US | disclosed |
| US-5658889-A | ADMINISTERING 5-AMINO-4-IMIDAZLECARBOXAMIDE RIBOSIDE WHICH BINDS ADENOSINE MONOPHOSPHATE SITE OF FRUCTOSE-1,6-DIPHOSPHATASE | GENSIA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0427799-B1 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE | GENSIA PHARMA (US) | 1994-11-30 | — | — | EP | disclosed |
| EP-0427799-A4 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE | — | 1991-07-24 | — | — | EP | disclosed |
| EP-0427799-A1 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE. | GENSIA PHARMA (US) | 1991-05-22 | — | — | EP | disclosed |
| WO-1990009163-A2 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE | GENSIA PHARMACEUTICALS, INC. (US) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | TDO2, BLVRB, INMT | FBP1 1134/4885AMDHD2 258/4885IGF2R 2010/4885 |
| US-20130040908-A1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS | MTAP, RNMT, NUDT1 | FBP1 1647/4885AMDHD2 1220/4885IGF2R 1310/4885 |
| US-20010019823-A1 | ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES | PNP, TREH, XDH | FBP1 120/4885AMDHD2 122/4885IGF2R 806/4885 |
| US-20260125713-A1 | PRODUCTION OF MOLECULES BY PERIPLASMIC ENZYMATIC CATALYSIS | MGAM, MRPL21, NOTUM | FBP1 134/4885AMDHD2 562/4885IGF2R 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.